Literature DB >> 28258378

Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis.

Kavish R Patidar1, Leroy R Thacker2, James B Wade3, Melanie B White1, Edith A Gavis1, Andrew Fagan1, Richard K Sterling1, Michael Fuchs1, Mohammad S Siddiqui1, Scott Matherly1, Richard T Stravitz1, Arun J Sanyal1, Puneet Puri1, Velimir A Luketic1, Jasmohan S Bajaj4.   

Abstract

BACKGROUND: Patient-Reported Outcomes Measurement Information System (PROMIS) tools can identify health-related quality of life (HRQOL) domains that could differentially affect disease progression. Cirrhotics are highly prone to hospitalizations and re-hospitalizations, but the current clinical prognostic models may be insufficient, and thus studying the contribution of individual HRQOL domains could improve prognostication. AIM: Analyze the impact of individual HRQOL PROMIS domains in predicting time to all non-elective hospitalizations and re-hospitalizations in cirrhosis.
METHODS: Outpatient cirrhotics were administered PROMIS computerized tools. The first non-elective hospitalization and subsequent re-hospitalizations after enrollment were recorded. Individual PROMIS domains significantly contributing toward these outcomes were generated using principal component analysis. Factor analysis revealed three major PROMIS domain groups: daily function (fatigue, physical function, social roles/activities and sleep issues), mood (anxiety, anger, and depression), and pain (pain behavior/impact) accounted for 77% of the variability. Cox proportional hazards regression modeling was used for these groups to evaluate time to first hospitalization and re-hospitalization.
RESULTS: A total of 286 patients [57 years, MELD 13, 67% men, 40% hepatic encephalopathy (HE)] were enrolled. Patients were followed at 6-month (mth) intervals for a median of 38 mths (IQR 22-47), during which 31% were hospitalized [median IQR mths 12.5 (3-27)] and 12% were re-hospitalized [10.5 mths (3-28)]. Time to first hospitalization was predicted by HE, HR 1.5 (CI 1.01-2.5, p = 0.04) and daily function PROMIS group HR 1.4 (CI 1.1-1.8, p = 0.01), independently. In contrast, the pain PROMIS group were predictive of the time to re-hospitalization HR 1.6 (CI 1.1-2.3, p = 0.03) as was HE, HR 2.1 (CI 1.1-4.3, p = 0.03).
CONCLUSIONS: Daily function and pain HRQOL domain groups using PROMIS tools independently predict hospitalizations and re-hospitalizations in cirrhotic patients.

Entities:  

Keywords:  Cirrhosis; Healthcare-related quality of life; Hepatic encephalopathy; Patient-Reported Outcomes Measurement Information System; Patient-reported outcomes

Mesh:

Year:  2017        PMID: 28258378     DOI: 10.1007/s10620-017-4509-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  44 in total

Review 1.  The impact of liver disease on health-related quality of life: a review of the literature.

Authors:  Lisa M Martin; Michael J Sheridan; Zobair M Younossi
Journal:  Curr Gastroenterol Rep       Date:  2002-02

2.  Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease--the LDQOL 1.0.

Authors:  I M Gralnek; R D Hays; A Kilbourne; H R Rosen; E B Keeffe; L Artinian; S Kim; D Lazarovici; D M Jensen; R W Busuttil; P Martin
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

3.  Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis.

Authors:  C Acharya; N S Betrapally; P M Gillevet; R K Sterling; H Akbarali; M B White; D Ganapathy; A Fagan; M Sikaroodi; J S Bajaj
Journal:  Aliment Pharmacol Ther       Date:  2016-11-20       Impact factor: 8.171

4.  Gastrointestinal symptoms in patients with liver cirrhosis are linked to impaired quality of life and psychological distress.

Authors:  Eva Fritz; Johann Hammer
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-04       Impact factor: 2.566

5.  An automated model using electronic medical record data identifies patients with cirrhosis at high risk for readmission.

Authors:  Amit G Singal; Robert S Rahimi; Christopher Clark; Ying Ma; Jennifer A Cuthbert; Don C Rockey; Ruben Amarasingham
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-13       Impact factor: 11.382

6.  Liver transplantation significantly improves global functioning and cerebral processing.

Authors:  Vishwadeep Ahluwalia; James B Wade; Melanie B White; HoChong S Gilles; Douglas M Heuman; Michael Fuchs; Edith A Gavis; Andrew Fagan; Felicia Tinsley; Dinesh Ganapathy; Leroy R Thacker; Richard K Sterling; R Todd Stravitz; Puneet Puri; Arun J Sanyal; Muhammad S Siddiqui; Scott Matherly; Velimir Luketic; Joel Steinberg; F Gerard Moeller; Jasmohan S Bajaj
Journal:  Liver Transpl       Date:  2016-10       Impact factor: 5.799

7.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

Review 8.  Health related quality of life in people with advanced chronic liver disease.

Authors:  James G Orr; Tara Homer; Laura Ternent; Julia Newton; Calum J McNeil; Mark Hudson; David E J Jones
Journal:  J Hepatol       Date:  2014-07-07       Impact factor: 25.083

9.  Association Between Psychological Distress and Liver Disease Mortality: A Meta-analysis of Individual Study Participants.

Authors:  Tom C Russ; Mika Kivimäki; Joanne R Morling; John M Starr; Emmanuel Stamatakis; G David Batty
Journal:  Gastroenterology       Date:  2015-02-11       Impact factor: 22.682

10.  Risk factors for frequent readmissions and barriers to transplantation in patients with cirrhosis.

Authors:  Swaytha Ganesh; Shari S Rogal; Dhiraj Yadav; Abhinav Humar; Jaideep Behari
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

View more
  3 in total

1.  Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.

Authors:  Guy Neff; Woodie Zachry
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

Review 2.  Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues.

Authors:  Sara Montagnese; Jasmohan S Bajaj
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

3.  Validation of a Simple Quality-of-Life Score for Identification of Minimal and Prediction of Overt Hepatic Encephalopathy.

Authors:  Mette Munk Lauridsen; Peter Jepsen; Charlotte Wilhelmina Wernberg; Ove B Schaffalitzky de Muckadell; Jasmohan S Bajaj; Hendrik Vilstrup
Journal:  Hepatol Commun       Date:  2020-07-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.